First Day of DEA Rescheduling Hearing: DEA, FDA Highlight Testimony That Cannabis Is Safer Than Alcohol and Opioids

On the first day of the DEA rescheduling hearing, counsel for the DEA and FDA emphasized testimony regarding cannabis’s medical benefits and its relative safety compared with alcohol and opioids. Bipartisan lawmakers predicted that congressional efforts to block the rescheduling would likely fail. Observers characterize the hearing as one of the most significant public proceedings in U.S. cannabis policy history, and say the DEA’s Schedule III reclassification process has effectively reached an irreversible stage.

For the full article, please visit the original source link below. CannabisInsight curates and summarizes key news from the global cannabis and hemp industry.